ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Celastrol-Loaded Conductive Hydrogel Mitigates Myocardial Ischemia-Reperfusion Injury and Restores Electrophysiological Function.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Myocardial ischemia-reperfusion injury (MIRI) remains an unresolved clinical challenge that severely limits the prognosis of patients undergoing revascularization. Through a phenotype-guided antioxidant screening workflow, celastrol (CLT) was selected as a bioactive compound for integration into a locally retained conductive hydrogel platform. However, the clinical translation of CLT is limited by poor aqueous solubility and potential systemic toxicity. To overcome these limitations, we developed an injectable F127DA/GelMA/PEDOT:PSS/celastrol hydrogel (FGPC) for the localized and sustained delivery of CLT. The FGPC hydrogel, composed of Gelatin methacryloyl (GelMA), Pluronic F127 diacrylate (F127DA) , and conductive poly(3,4-ethylenedioxythiophene):poly(styrenesulfonate) (PEDOT:PSS), exhibits favorable mechanical properties, enhanced electrical conductivity, local retention, and controlled drug release. In vitro, FGPC effectively reduced reactive oxygen species (ROS), supported cardiomyocyte structural organization, and enhanced gap-junction coupling. In a rat MIRI model, local FGPC delivery attenuated acute oxidative stress, suppressed inflammatory activation, and reduced neutrophil extracellular trap formation. Transcriptomic analysis further revealed downregulation of inflammatory pathways, including the IL-17 signaling pathway and S100a8/S100a9-related inflammatory mediators. During the chronic repair phase, FGPC improved cardiac function, reduced fibrosis, restored connexin 43 expression, reduced inducible ventricular arrhythmia susceptibility, and promoted angiogenesis without obvious systemic toxicity. This study presents a locally retained conductive hydrogel platform that combines CLT-mediated microenvironment modulation with electrical support, providing a potential strategy for myocardial repair after reperfusion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.